Intellia Therapeutics

NTLA

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has partnerships with Novartis and Regeneron.

Intellia Therapeutics has been a target of short sellers for a while. The current short interest of 31.35% is roughly at the average of the last 12 months (30.51%).